Clinical outcomes of inhaled Technosphere insulin in adults with type 1 diabetes: A systematic review and meta-analysis

For millions of people living with type 1 diabetes, the daily rhythm of life is dictated by the need to replace a hormone the body can no longer make. This hormone, insulin, acts as a key that unlocks cells to let sugar in for energy. In a healthy body, the pancreas releases a steady background amount of insulin and then spikes a precise burst of this hormone the moment food arrives. People with type 1 diabetes must mimic this pattern manually. They take a long-acting insulin once or twice a day to cover their basic needs, and then they must inject a rapid-acting dose before every meal. While modern injections work well, they are not perfect. The medicine takes time to travel from the skin into the bloodstream, often arriving too late to match the immediate surge of sugar from a meal, or lingering too long after the food is gone. This mismatch can lead to high blood sugar right after eating and low blood sugar hours later. Furthermore, the requirement for lifelong needle injections is a heavy burden, causing physical discomfort and mental fatigue that can make sticking to the treatment plan difficult.

Scientists have long searched for a way to deliver insulin that feels more like the body's natural process and avoids the needle. One such method involves breathing insulin into the lungs, where it is absorbed directly into the blood. This approach, known as inhaled insulin, was designed to act much faster than injections, reaching peak levels in the bloodstream within minutes rather than an hour. A specific version of this inhaled medicine, called Technosphere insulin, has been available for adults with type 1 diabetes. However, while it offers a needle-free option, doctors and researchers have debated whether it controls blood sugar as effectively as traditional injections and whether breathing it in is safe for the lungs over the long term. To settle these questions, a team of researchers gathered data from multiple clinical trials to see how this inhaled option truly performs in the real world.

The researchers conducted a comprehensive review of six separate, high-quality studies involving 1,270 adults with type 1 diabetes. In these studies, participants were randomly assigned to use either the inhaled Technosphere insulin or the standard rapid-acting insulin delivered through injections or pumps. The scientists looked closely at the primary goal of diabetes treatment: keeping blood sugar levels in a healthy range. They measured this by looking at a standard blood test called HbA1c, which reflects average blood sugar over several months. The analysis showed that the inhaled insulin was just as effective as the injections. The difference in blood sugar control between the two groups was so small that it was statistically indistinguishable, confirming that the inhaled option is a viable alternative for managing the disease.

Beyond blood sugar control, the study uncovered a surprising benefit regarding body weight. In the trials, adults using the inhaled insulin lost an average of about 1.55 kilograms more than those using the standard injections. This weight reduction is significant because many diabetes treatments can lead to weight gain, which complicates long-term health. The researchers suggest this might happen because the inhaled insulin leaves the body faster than injected insulin, reducing the time the body is exposed to high levels of the hormone, which can otherwise encourage fat storage. While the exact mechanism was not fully proven in these trials, the consistent drop in weight across the studies is a clear and positive finding.

Safety was the other major focus of the review, particularly concerning the lungs. Because the medicine is breathed in, there was a legitimate concern that it might irritate the airways or damage lung function. The data showed that the inhaled insulin did not cause any significant decline in lung function, as measured by a standard test that checks how much air a person can exhale. However, the medicine did cause a specific side effect: coughing. The review found that coughing was much more common in the group using the inhaled insulin compared to the injection group. Despite this high frequency, the cough was typically dry, mild, and temporary, often fading as the day went on. Crucially, very few people stopped using the medicine because of the cough, and there was no increase in serious lung problems or other severe health events.

The researchers also examined how well the medicine worked when people needed to correct high blood sugar after a meal. They found that the inhaled insulin worked best when patients followed specific rules for taking extra doses if their blood sugar remained high. In studies where patients were diligent about these correction doses, their blood sugar levels stayed in the healthy range for longer periods. This suggests that while the medicine is effective, it requires a bit more attention and perhaps more frequent monitoring than a simple injection. The study authors noted that the trials were open-label, meaning both the patients and the doctors knew which treatment was being used, which can sometimes influence how results are reported. Additionally, most of the studies were funded by the company that makes the medicine, which is a factor that requires careful consideration.

Ultimately, this large review confirms that inhaled Technosphere insulin is a safe and effective option for adults with type 1 diabetes who want to avoid needles. It controls blood sugar just as well as traditional injections and offers the added benefit of helping patients lose a small amount of weight. While the frequent coughing is a notable side effect, it rarely forces people to stop treatment, and it does not appear to harm lung function. The findings suggest that for those willing to manage the specific dosing requirements, this needle-free method offers a meaningful alternative to the daily routine of injections, providing a different path toward managing a complex condition.